8BT Stock Overview
A clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
BriaCell Therapeutics Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.49 |
| 52 Week High | CA$5.25 |
| 52 Week Low | CA$0.37 |
| Beta | 1.91 |
| 1 Month Change | -29.50% |
| 3 Month Change | -7.55% |
| 1 Year Change | -86.31% |
| 3 Year Change | -94.40% |
| 5 Year Change | 2,127.27% |
| Change since IPO | 92.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8BT | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -14.8% | -2.9% | -2.6% |
| 1Y | -86.3% | -14.7% | 6.9% |
Return vs Industry: 8BT underperformed the German Biotechs industry which returned -14.7% over the past year.
Return vs Market: 8BT underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| 8BT volatility | |
|---|---|
| 8BT Average Weekly Movement | 25.6% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8BT's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8BT's weekly volatility has increased from 19% to 26% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 16 | Bill Williams | briacell.com |
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.
BriaCell Therapeutics Corp. Fundamentals Summary
| 8BT fundamental statistics | |
|---|---|
| Market cap | €24.47m |
| Earnings (TTM) | -€15.90m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.5x
P/E RatioIs 8BT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8BT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$16.60m |
| Earnings | -US$16.60m |
Last Reported Earnings
Oct 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 8BT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 00:20 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/10/31 |
| Annual Earnings | 2024/07/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BriaCell Therapeutics Corp. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Emily Bodnar | H.C. Wainwright & Co. |
| Ashok Kumar | ThinkEquity LLC |